Ananda Developments PLC - London-based pharmaceutical firm, which is developing cannabinoid-based medicines for chronic pain conditions - Notes the Food Standards Agency’s and Food Standards Scotland’s recently published Safety Assessment: ’Cannabidiol (CBD) isolate as a novel food for use in a range of food categories including food supplements’. ‘Ananda believes that the FSA-FSS assessment underscores its strategy of developing CBD formulations as licensed medicines, with Randomised Controlled Trials evidence, to allow for accurate and potentially higher doses,’ it says.

Chief Executive Melissa Sturgess comments: ‘We identified several years ago that the right path to build shareholder value in the CBD space is via clinical trials, evidence and regulatory approvals. This latest FSA-FSS report highlights that we were correct in our assessment, and we look forward to delivering the results of our clinical trials and further initiatives in this area.’

Current stock price: 0.308 pence

12-month change: down 51%

Copyright 2024 Alliance News Ltd. All Rights Reserved.